SEC Comment Letter 0000000000-22-012266 to Cerevel Therapeutics Holdings, Inc. (CIK 0001805387)
Cerevel Therapeutics Holdings, Inc. (CIK 0001805387)
Date: Nov. 10, 2022 · CIK: 0001805387 · Accession: 0000000000-22-012266
AI Filing Summary & Sentiment
File numbers found in text: 333-268235
Letter
United States securities and exchange commission logo November 10, 2022 N. Anthony Coles Chief Executive Officer Cerevel Therapeutics Holdings, Inc. 222 Jacobs Street, Suite 200 Cambridge, MA 02141 Re:Cerevel Therapeutics Holdings, Inc. Registration Statement on Form S-3 Filed November 8, 2022 File No. 333-268235 Dear N. Anthony Coles: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nicole Daley
Show Raw Text
United States securities and exchange commission logo
November 10, 2022
N. Anthony Coles
Chief Executive Officer
Cerevel Therapeutics Holdings, Inc.
222 Jacobs Street, Suite 200
Cambridge, MA 02141
Re:Cerevel Therapeutics Holdings, Inc.
Registration Statement on Form S-3
Filed November 8, 2022
File No. 333-268235
Dear N. Anthony Coles:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Nicole Daley